Pharmaxis Strengthens Clinical Development Oncology Capability with The Appointment of Dr Jana Baskar as Chief Medical Officer
Release Date: 01/07/2022 8:40am
Pharmaxis Limited (ASX:PSX), a clinical stage drug development company developing novel therapies to treat inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Jana Baskar to the role of Chief Medical Officer.
Dr Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies.
“We are delighted to welcome Dr Baskar to Pharmaxis, where his deep experience leading clinical programs will be an asset to the continued advancement of our pipeline,” commented Gary Phillips, Chief Executive Officer of Pharmaxis. “Dr Baskar brings significant oversight, clinical development and strategic expertise, having previously guided numerous programs through all phases of development. His extensive background and experience will be particularly valuable as the Company progresses its lead asset, PXS-5505, towards clinical proof of concept in myelofibrosis and other oncology indications.”
Categories: News and Media